Inhibiting miR-22 Alleviates Cardiac Dysfunction by Regulating Sirt1 in Septic Cardiomyopathy

Runze Wang1,2, Yuerong Xu3, Wei Zhang1

  • 1Department of Cardiology, Tangdu Hospital, The Fourth Military Medical University, Xi'an, China.

Insights

Targeting microRNA-22 (miR-22) shows promise for treating septic cardiomyopathy. Inhibiting miR-22 protects the heart by increasing autophagy and reducing apoptosis, offering a potential new therapeutic strategy.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Genetics

Background:

  • Septic cardiomyopathy is characterized by high morbidity and mortality.
  • The precise role of microRNA-22 (miR-22) in this condition remains unclear.

Purpose of the Study:

  • To investigate the role of miR-22 in septic cardiomyopathy.
  • To elucidate the underlying molecular mechanisms of miR-22's action.

Main Methods:

  • Utilized miR-22 cardiac-specific knockout (miR-22cKO) and transgenic (miR-22cOE) mice subjected to cecal ligation and puncture (CLP) to induce sepsis.
  • Performed echocardiography, measured serum cardiac biomarkers (LDH, CK-MB), and assessed apoptosis, autophagy, and mitochondrial function.
  • Validated findings in primary cardiomyocytes treated with lipopolysaccharide (LPS) in vitro.

Main Results:

  • miR-22cKO mice exhibited alleviated cardiac dysfunction, reduced serum LDH and CK-MB levels post-CLP.
  • Knockout of miR-22 led to decreased apoptosis, enhanced autophagy, and improved mitochondrial function.
  • Inhibition of miR-22 promoted autophagic flux, evidenced by increased LC3II/GAPDH ratio and decreased p62 levels.

Conclusions:

  • Cardiac-specific knockout of miR-22 confers a cardioprotective effect against sepsis.
  • miR-22 inhibition may protect the heart by upregulating autophagy and downregulating apoptosis, potentially via sirt1.
  • Targeting miR-22 presents a novel therapeutic strategy for septic cardiomyopathy.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
104
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
166
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
46